EyePoint Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EYPT research report →
Companyeyepointpharma.com
EyePoint Pharmaceuticals, Inc. , a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.
- CEO
- Jay S. Duker
- IPO
- 2005
- Employees
- 165
- HQ
- Watertown, MA, US
Price Chart
Valuation
- Market Cap
- $1.05B
- P/E
- -3.96
- P/S
- 137.63
- P/B
- 4.66
- EV/EBITDA
- -3.56
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.51%
- Op Margin
- -3700.89%
- Net Margin
- -3566.63%
- ROE
- -110.54%
- ROIC
- -112.37%
Growth & Income
- Revenue
- $31.37M · -27.50%
- Net Income
- $-231,962,000 · -77.25%
- EPS
- $-3.17 · -36.64%
- Op Income
- $-243,434,000
- FCF YoY
- -86.82%
Performance & Tape
- 52W High
- $19.11
- 52W Low
- $5.46
- 50D MA
- $13.58
- 200D MA
- $13.94
- Beta
- 1.77
- Avg Volume
- 1.08M
Get TickerSpark's AI analysis on EYPT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Ribeiro Ramiro | other | 2,437 |
| Apr 17, 26 | Ribeiro Ramiro | other | 2,437 |
| Apr 17, 26 | Ribeiro Ramiro | sell | 2,437 |
| Mar 23, 26 | Duker Jay S. | other | 76,766 |
| Mar 23, 26 | Duker Jay S. | other | 97,500 |
| Mar 23, 26 | Duker Jay S. | other | 97,500 |
| Mar 23, 26 | Duker Jay S. | other | 52,500 |
| Mar 23, 26 | Duker Jay S. | other | 52,500 |
| Mar 23, 26 | Duker Jay S. | other | 76,766 |
| Mar 16, 26 | Duker Jay S. | buy | 1,500 |
Our EYPT Coverage
We haven't published any research on EYPT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EYPT Report →